Taxanes In Lung Cancer Therapy (Hardbound - 1998)

About the Book
Exploring topics from pharmacokinetics and tubulin targets to schedule dependence and clinical toxicity profiles, this timely work compiles-in a single source-current information on taxanes and their superior activity against small-cell and non-small-cell lung cancer that will enable researchers to optimize present and future palliative and curative strategies.
Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving

novel mechanisms of action for paclitaxel and docetaxel

paclitaxel exposure duration as well as drug combinations and sequences

phase II trials with paclitaxel in chemotherapy-na ve advanced non-small-cell lung cancer (NSCLC) patients

the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC

comparisons of survival duration, response rates, and toxicity between taxol and other regimens

the activity of docetaxel against platinum-resistant/refractory NSCLC

and much more
Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.